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cerations may be eaten out, and patches of membranes formed [4] ." Aspergillus infection of the airways, with varied degrees of mucoid impaction and pseudomembrane formation, has been described in five human immunodeficiency virus (HIV)-infected patients, but only three of these patients had evidence of tissue invasion [5] [6] [7] . The incidence of invasive aspergillosis in patients with HIV disease is not known, but it is an unusual opportunistic infection in this population. Fungi other than Cryptococcus neoformans caused <1% of all pulmonary infections in patients with AIDS in one large series [8] , with none reportedly due to Aspergillus. The low incidence of reported disease may in part be due to the difficulties inherent in the antemortem diagnosis of invasive aspergillosis. However, even in a large autopsy series, aspergillosis was found in only 1.4% of pulmonary infections in patients with AIDS [9] . Nevertheless, aspergillosis in patients with AIDS is being reported with increased frequency [5, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
We describe four patients with AIDS who developed severe airway infection due to Aspergillus species. The pertinent clinical and demographic characteristics are outlined in table 1 . In addition, a review of invasive tracheobronchitis due to infection with Aspergillus, including a discussion of airway disease due to Aspergillus in patients with HIV infection, is presented.
Methods
Three patients presented with ulcerative bronchitis and one presented with ulcerative tracheitis due to Aspergillus species between 17 May 1990 and 21 May 1991. Three patients were referred to the Santa Clara Valley Medical Center (San Jose, CA) for evaluation and treatment, and the other patient was cared for at the Cedars-Sinai Medical Center All of the patients underwent bronchoscopic examination with bronchoalveolar lavage (BAL), and one underwent transbronchial biopsies. BAL specimens at each institution were cultured for bacteria (including Legionella species), mycobacteria, fungi, and virus (including cytomegalovirus [CMV]). Cytological examinations, including staining with Wright's and Grocott-Gomori methenamine-silver nitrate (GMS), stains were performed on BAL specimens from all four patients. Sputum specimens were obtained at baseline for fungal culture from two patients. Endobronchial or endotracheal biopsy specimens were cultured for fungus for all four patients. Two of the three patients who died were examined post-mortem. Three patients received itraconazole as part of an open trial of itraconazole in the treatment of invasive aspergillosis by the National Institute of Allergy and Infectious Diseases Mycoses Study Group, and one obtained the drug outside of the study setting. Serum concentrations of itraconazole were determined by bioassay as described elsewhere [20] .
A review of the literature was conducted by a MEDLINE search with use of key terms (including aspergillus, bronchitis, tracheobronchitis, airway disease, HIV, and AIDS) as well as by cross-referencing published articles. . This entity was recently described in three individuals with HIV infection; one of these cases progressed to invasive bronchial disease and dissemination despite therapy [5] . Two French authors have described three patients with a similar entity, "bronchique obstructive aspergillus" [6, 23] , but the distinction between invasive disease and noninvasive disease in these cases is not clear. One of these three patients developed widely disseminated disease despite antifungal therapy, and one remained free of disease following antifungal therapy [23] . The third patient, a young man with HIV infection, presented with dyspnea, mucous plugging, superficial mucosal ulcerations, and hyphal invasion [6] . Despite having received only corticosteroids, he reportedly remains free of disease more than 6 years later (Dr. V. LeGros, personal communication).
Results

Report of Cases
The information provided in these case reports is summarized in table 3. Reportedly, only 16 of the 58 cases were diagnosed before death; 34 were diagnosed post-mortem or presented as part of an autopsy series. Several of these latter case reports lack information necessary for a complete assessment of factors pertinent to the diagnosis of invasive fungal disease. The median age of affected patients was 44 years, with a range of 2.5-87 years. Approximately 73% of the patients so described were immunoincompetent, including six patients who had solid tumors (three lung, one breast, one rectum, and one kidney) and one patient who had pancytopenia secondary to gold therapy. Neutropenia was an underlying factor in 55% of patients; cytotoxic chemotherapy (or radiation therapy) had been administered to 61% and corticosteroids, to 61%. Five patients, however, were reported to have none of these well-described risk factors for invasive fungal disease, including a patient with diabetes, one who had lung cancer, a former alcoholic, and an HIV-infected patient [34] [35] [36] . At least 45% had underlying pulmonary disease, including seven patients with histological evidence of lung rejection [26, 29] . Twenty-six (81%) of 32 patients were described as symptomatic. The most frequent complaints, in descending order of frequency, were cough (in 12), fever (in 11), dyspnea (in 11), chest pain (in 3), and hemoptysis (in 2). Nineteen patients had abnormal chest roentgenograms, four of which were possibly attributable to other causes, but chest roentgenograms were normal for at least 9 (32%) of 28 patients described [ . Clinical outcome was described in 28 patients; despite therapy in 22 patients, only 6 (21%) were described as "cured" of their disease.
Discussion
Aspergillus airway disease encompasses a variety of processes including saprophytic colonization, allergic bronchopulmonary aspergillosis, bronchocentric aspergillosis, mucoid impaction, obstructing bronchial aspergillosis, and tracheobronchitis. These clinical syndromes are seldom distinct, and features of each may overlap, as elegantly illustrated by Katzenstein et al. [41] , or may occur in a progressive fashion. For example, allergic bronchopulmonary aspergillosis is described as noninvasive, but cases with limited tissue invasion have been described [42, 43] . "Bronchocentric mycosis," with features resembling bronchocentric granulomatosis, has recently been described in two transplant recipients; however, both had invasive disease and one had inspissated secretions [44] . Mucoid impaction, a localized form of aspergillosis characterized by bronchial casts of mucus and mycelia, is associated with allergic bronchopulmonary aspergillosis [41] . Although ordinarily considered noninvasive, superficial erosion with subsequent ulceration and invasion may ensue. In addition, mucoid impaction may be a prominent (and occasionally fatal) feature in cases of invasive tracheobronchitis, particularly in patients with underlying airway disease such as that due to rejection of a transplanted lung [3, 21, 39] . Mucoid impaction also preceded the development of invasive disease in one of three recently described cases of obstructing bronchial aspergillosis in HIV disease [5] .
Although it is apparent that the pathogenesis of these forms ofaspergillosis is dependent on host factors, the immunologic mechanisms underlying these processes have not been substantially illuminated. It may be helpful to consider their evolution as manifestations of different types of host responses, with varying degrees of allergic response, mucus formation, inability to clear secretions, and tissue invasion. Anatomic location may also be important in the pathogenesis of these responses. A classification of tracheobronchitis recently was proposed to differentiate among diffuse bronchitis/tracheitis, ulcerative bronchitis/tracheitis, and pseudomembranous bronchitis/tracheitis [26] . A classification system for aspergillus airway disease that provides clinically meaningful information based on pathophysiological mechanisms, anatomic and histological features, and potential for invasion, which is correlated to clinical outcome, is needed.
The clinical and histological features of our four patients with AIDS and ulcerative tracheobronchitis are similar to those of the patients without AIDS reviewed. All four of our patients were severely immunocompromised. One had received corticosteroids, one was neutropenic at presentation, and one had both of these well-defined risk factors for invasive aspergillosis. One patient, who did not have histological evidence of invasive disease, had neither of these well-defined risk factors at presentation, although he had a history of neutropenia. This patient had a preexisting tracheal ulcer that probably was secondarily infected with Aspergillus. PCP preceded the diagnosis of aspergillosis in the other three patients. Aspergillus infection of the lung has occurred in patients with preexistent cavitary disease caused by PCP [45] . A possible association between invasion by Aspergillus and CMV, which was responsible for clinically invasive retinal disease in two of these patients and identified in BAL fluid in one of them, has also been raised [5, 26] .
All four of the patients had symptoms referable to the airways or lungs, but only two had abnormal chest roentgenograms. Pulmonary parenchymal involvement and dissemination were documented at presentation in only one case. Although transbronchial biopsy specimens and cultures were CID 1993;17 (September) negative for Aspergillus for a second patient, parenchymal lung involvement probably occurred concurrently with PCP at presentation and was subsequently documented at autopsy. Both the incidence of parenchymal lung involvement (50%) and the incidence of dissemination (25%) are similar to those found in the review of other cases. Tracheobronchial disease presented grossly on bronchoscopic examination in our four patients with varied degrees of erythema and edema of the airway mucosa, with one to multiple ulcerative lesions, and occasionally with exophytic nodules and plaque-like lesions. In contrast to the cases reviewed, which included several patients with HIV disease [5, 7] , we found no clinically apparent pseudomembrane formation and mucoid impaction in any of our HIV-infected patients (table 4). Involvement of the cartilage was seen in the case of ulcerative tracheitis. Only a few colonies of Aspergillus species grew from both lavage and biopsy specimens despite evidence of significant hyphal invasion. These data are in apparent contradiction to a recent report suggesting that higher colony counts may correlate with the severity of invasive bronchial disease in heart-lung transplant recipients [26] . The occurrence of isolated airway infection with Aspergillus without apparent disease in some patients with HIV infection suggests that such colonization has little potential for invasion in these individuals [15, 46] . In one retrospective analysis, Aspergillus was isolated from the respiratory secretions of 26 HIV-infected patients, but only four (15%) had evidence of invasive disease at autopsy [15] .
All four of our patients received itraconazole. [5] . Whether this apparent increased frequency of airway disease in patients with AIDS is a result of more vigilant and frequent examination of the tracheobronchial tree in this patient population is not known. It is probable that the initial disease in these patients is superficial, involving the mucosa, and may imply abnormalities in mucus production or ciliary function in HIV-infected patients. In some patients, this initial disease progresses to ulceration and then invasion.
Fungal tracheobronchitis has been described as a rare but relatively benign process, causing few symptoms with little potential for invasion, apparently identified as an incidental finding at postmortem examination in otherwise terminally ill individuals [40] . Nevertheless, our review demonstrates that invasive tracheobronchitis due to Aspergillus can be a rapidly progressive and fatal illness in -40% of patients so affected. Death occurs as a result of direct intrathoracic invasion and subsequent dissemination or, less commonly, from airway obstruction due to mucoid impaction or pseudomembrane formation. Respiratory symptoms, such as persistent cough, are common, but chest roentgenograms may be normal. Even a single colony of Aspergillus in sputum may signal invasive disease in symptomatic patients with AIDS and necessitates prompt investigation of the tracheobronchial tree. Despite histological evidence of only limited bronchial mucosal invasion, tracheobronchitis may herald occult or incipient development of pulmonary parenchymal involvement and dissemination in the appropriate host setting.
